BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Alpha Compute Corp readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Alpha Compute Corp's drugs run\, 
 from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04969315-2782@assetmemo.bio
DTSTAMP:20261121T004016Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:TT-10: Phase 1/2 readout est. (NCT04969315)
DESCRIPTION:TT-10\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: TT-4 an
 d TT-10 as Single Agents and in Combination in Subjects With Advanced Sele
 cted Solid Tumors and Pleural Mesothelioma\nEstimated primary completion: 
 1 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tt-1
 0#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 969315
URL:https://assetmemo.bio/drug/tt-10#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
